Industries
Ketamine clinic marketing measured to the started treatment series.
A ketamine inquiry has to clear a screening call, a medical eligibility review, and a consult before anyone sits down for a first infusion. Most clinic marketing stops counting at the inquiry, which is the one step that tells an owner almost nothing.
A ketamine clinic sells something unusual: a series of treatments to a patient who has usually already tried medication and therapy, who has researched the clinic carefully, and who still has to pass a medical screening before anyone agrees to treat them. Ketamine clinic marketing that reports on inquiries is counting the step with the least information in it. The event that tells an owner a campaign worked is the started treatment series - a patient who cleared screening, came in for a consult, and sat down for a first infusion or a first Spravato session.
That sequence sets ketamine practices apart from the groups covered under marketing for multi-location healthcare groups. A multi-location medical group is mostly insurance-mediated, and its outcome is a booked consultation recorded in an EMR. A ketamine clinic is largely self-pay for IV treatment, partly insurance-billed for Spravato, and screens out a meaningful share of the people who contact it on purpose. It also differs from the elective work covered under dental practice marketing: a dental patient chooses a procedure, while a ketamine patient is usually choosing whether to try a treatment at all, on a timeline set by how they are feeling and whether someone they trust recommended it.
The value sits in the series, and in the maintenance infusions some patients return for afterward. A single consult is worth little on its own. A patient who completes a series and stays with the clinic for boosters is worth a great deal, which is why a campaign that produces cheap inquiries from people who fail screening can look efficient on a dashboard while costing the clinic money.
What makes ketamine clinic measurement hard
- The eligibility screen
- Every new patient goes through a screening call and a medical review before treatment, and some are declined for clinical reasons. An inquiry that was never going to be eligible counts the same as a strong candidate in every ad platform, so cost per lead mixes the two together.
- Research and referral lag
- Patients often read about ketamine for weeks, talk to a therapist or psychiatrist, and contact a clinic long after the ad or article that first reached them. By the time they book, the original click has usually aged out of the platform's attribution window.
- Series value hidden behind a single visit
- The outcome that matters is a started series and the maintenance that may follow it. Platforms see one conversion at the moment of inquiry and nothing about what that patient went on to do.
- Two payment paths in one clinic
- Spravato typically runs through benefits verification and prior authorization, and IV ketamine mostly through self-pay and financing. A campaign can be strong for one and weak for the other, and a single blended number hides which.
- Advertising restrictions
- Google and Meta both restrict ads that promote prescription drugs. Disapprovals, limited delivery, and certification requirements decide whether some campaigns run at all, which shapes what can be tested and measured.
- Privacy on mental health pages
- A tracking pixel on a depression or PTSD treatment page can pass more to an ad platform than the clinic intends. Measurement has to be built so condition and identity never leave the clinic's own systems.
How we measure to the started series
The connection runs through the clinic's own records. Most ketamine practices work in an EHR built for psychiatric or infusion care, such as Osmind, or a general platform like Tebra or IntakeQ, and nearly all of them can produce a scheduled export of appointments and their status. We match that export back to the scored call or form that started each patient's path, using non-clinical identifiers the clinic already holds: a phone number, a booking date, a record ID. That matching is the core of our marketing attribution consulting, adapted to a clinic that has to protect more about its patients than most.
Calls are scored before they count. A patient asking whether they qualify, a current patient rescheduling a booster, and a vendor calling the tracking line all connect a call; only the first is a new inquiry. Inquiries are then followed through each stage the clinic records - screening completed, eligible, consult held, first treatment - so the report can show where a channel's patients stop.
Nothing that identifies a patient or their condition goes back to an ad platform. Conversions are sent as anonymous events with no health detail, and pages that describe conditions are checked so their tracking cannot leak what a visitor was reading about.
The result is cost per started series by channel, with IV ketamine and Spravato reported separately and referrals in their own column. That is the figure that tells an owner where the next month's budget should go.
Where the six mapped programs fit
Attribution comes first, because every other program is judged against the started series it produces. SEO builds visibility for the searches patients make once they are close to choosing a clinic - ketamine therapy or Spravato treatment in their city, a specific condition plus a treatment - where a smaller clinic can outrank a national chain on local relevance. Content marketing does more here than in most fields, since a prospective patient reads extensively about how ketamine works, what a session feels like, what it costs, and whether it is safe before contacting anyone; clear, accurate education is often what earns the first call. Non-brand paid search reaches patients who are actively looking for treatment, built within the advertising restrictions described above and checked against them before launch. Conversion rate optimization is mostly intake work: how quickly an inquiry gets a call back, how the screening conversation is handled, and how cost and financing are explained, since that is where eligible patients are most often lost. Email marketing carries patients through the gap between inquiry and consult, which can run for weeks while records are gathered or authorization is pending, and later supports booster scheduling for patients the medical team has recommended maintenance for.
What shows up in the monthly review
The monthly report follows every inquiry from the previous month through the stages the clinic records. For each channel it shows how many inquiries arrived, how many completed screening, how many were eligible, how many held a consult, and how many started a series. Read across a row, it tells the owner whether a channel is producing eligible patients or only volume.
Call review findings sit alongside it: how long new inquiries waited for a callback, which calls ended without a next step, and whether people asking about cost were given a clear answer. A clinic often finds that its biggest losses happen after the inquiry and before the consult, inside its own intake process, where no ad platform can see.
IV ketamine and Spravato get separate lines, because the reasons a patient stalls are different for each. A Spravato patient waiting on prior authorization needs a different follow-up than an IV patient comparing prices. Referrals get their own line too, so an owner can see which referring providers send patients who go on to start a series.
Reviewed monthly, these numbers catch problems while they can still be fixed: a slowdown in callback times, a campaign whose eligible rate is drifting down, a referral partner whose patients have stopped arriving. Results from real engagements appear on the proof hub only after the client behind them has approved the figures in writing, which is the standard any claim about this kind of measurement should meet.
Which services apply
Attribution
Attribution built to your revenue system, not the ad platform's.
SEO
Non-brand organic visibility measured per location.
Content marketing
Editorial measured by the deals it appeared in.
Paid search
Non-brand paid search judged on booked outcomes.
CRO
Testing run long enough, on real traffic, to mean something.
Email marketing
Lifecycle programs measured on incremental revenue.
Usually, yes, through a scheduled export rather than a live integration. Osmind, Tebra, IntakeQ, and most platforms ketamine practices run on can export appointment and status data in some form, and that export is enough to confirm whether a scored call or form became a completed screening, a consult, and a first infusion. The match uses non-clinical fields the clinic already holds, such as a phone number and an appointment date. Where a setup has no usable export, the audit says so before any work is scoped around it.
By keeping anything that could identify a patient or their condition away from the ad platforms entirely. Tracking on treatment and condition pages is reviewed before launch, conversions go back to Google or Meta as anonymous events with no health detail attached, and the matching between a campaign and a started series happens inside reporting the clinic controls. The ad platform learns that a valuable conversion happened. It never learns who the patient was or what they were treated for.
We can fix the parts that are fixable and be direct about the parts that are not. Ad platforms restrict promotion of prescription drugs, and ketamine terms trip those rules often, so whether a campaign runs depends on the clinic's certification status, how landing pages describe treatment, and which keywords and ad copy are in use. We audit all three and rebuild what is causing disapprovals. No outside party can guarantee approval, since the platform makes that decision, and an agency that promises otherwise is promising something it does not control.
No. They are different decisions with different paths. Spravato is usually billed to insurance and runs through benefits verification and prior authorization, while IV ketamine is mostly self-pay and turns on price, financing, and trust in the clinic. A blended report hides which of the two a campaign is actually producing, and the two often deserve different budgets, landing pages, and follow-up. We report them in separate columns from the first month.
Referrals get their own column and are never credited to a campaign. A patient sent by their therapist decided to seek treatment before any ad reached them, so counting that patient as marketing-sourced would overstate what the campaign did. Keeping referrals separate also makes them visible as a channel in their own right: which referring providers send patients who start a series, and whether that relationship is growing or quietly fading.
No. Clinical decisions, including who is eligible, what protocol a patient receives, and how many infusions a series includes, belong to the clinic's medical director. We are a marketing and measurement firm with no clinical role. What we report is where eligible patients drop out between inquiry and first infusion, so the clinic can see whether a gap is a marketing problem, an intake problem, or simply the screening doing its job.
See how many of your inquiries reach a first infusion.
A review that follows one month of inquiries through screening, consult, and the first infusion, by channel, and shows where eligible patients are being lost.